![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Celeris Corporation provides specialty clinical research to pharmaceutical, medical device and biotechnology manufacturers. For the six months ended 6/99, revenues rose 58% to $4.3 million. Net loss from continuing operations totalled $2.2 million, up from $64 thousand. Revenues reflect expanded service capabilities and a higher volume of consulting services performed. Loss reflects higher general and administrative expenses associated with the expanded service offerings. .... Celeris is threatened by delisting because their market cap is too small for the nasdaq it is under $4Millions. People, do a good work. Let's bring this puppy to $2 and over and spare it the delisting. No secret: CLRS has around $9 Millions, or nearly $3 in CASH, and little debt. Their net equity is at $9.4MM. For the 9 months they posted $6.6MM revenues and a gross profit of 2.1MM Can you imagine buying $3 cash for $1 ??? | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |